Navigation Links
Abingdon Life Sciences, Inc. Announces Opening of Office in Carlsbad, Ca.

CARLSBAD, Calif., July 21 /PRNewswire/ -- Abingdon Life Sciences announces the formal opening of its offices in Carlsbad, California. The offices, located at 5963 La Place Court, Suite 107, are in the Carlsbad Airport Business Park adjacent to Palomar Airport. Abingdon Life Sciences, Inc. is a first-in-class Drug, Device, Diagnostic Development Management Organization (DDMO), focused on providing drug and device companies with superior services based on an integrated strategic development model. An integrated development model focuses on the Target Product Profile (TPP) concept, and allows a platform to be assessed by key areas of opportunity and risk from both scientific and business aspects.

Abingdon was founded on the principle that a proactive strategic approach to development will yield better outcomes. Abingdon's philosophy is to provide clients with a focused approach to product development by building synergistic partnerships that use significant expertise to achieve the best outcome. Global core-competencies include pre-clinical, regulatory strategy and submissions, clinical development, biostatistics, report writing and post-marketing obligations. Abingdon provides services to clients with products initially filed under IND, CTX, 505(b)(2), NDA, ANDA, PMA and 510k applications. Abingdon's senior executives provide personalized oversight and leadership of projects to ensure the best possible customer experience. Key alliances enable Abingdon to assist with cGMP services from formulation development for clinical trial supply through commercialization.

"Abingdon's approach is to reduce the noise in the development process and provide objective direction that outlines the risks and benefits of the potential development pathways. In the end, our goal is to assist our clients to streamline their development process and help make decisions that will achieve their goals. We believe this will ultimately reduce costs to our clients and speed the time to market," stated Aidan Nuttall, Ph.D., President and C.O.O., Abingdon Life Sciences, Inc.

About Abingdon Life Sciences, Inc.:

Abingdon Life Sciences, Inc. is a first-in-class Drug and Device Development Management Organization (DDMO) providing drug and device companies superior clinical and regulatory services based on an integrated strategic development model. Abingdon's senior executives provide personalized oversight and leadership of projects to ensure the best possible customer experience.

SOURCE Abingdon Life Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioTime, Inc. and Embryome Sciences, Inc. Sign Agreement With International Stem Cell Corporation to Provide Unique Human Stem Cell Lines for Research Use
2. Dow AgroSciences, Sangamo BioSciences Announce the Achievement of Key Milestones in Plant Agriculture Collaboration
3. Dow AgroSciences, Martek Biosciences Form Alliance to Bring Omega-3 Fatty Acids to Food Industry
4. Intellect Neurosciences, Inc. Grants License for Certain Patents and Patent Applications to Wyeth and Elan Pharma International Ltd.
5. Pressure BioSciences, Inc. to Discuss First Quarter 2008 Financial Results and Provide Business Update
6. RiverVest Venture Partners(R), a St. Louis-Based Venture Capital Firm Focusing on Life Sciences, Closes on Fund II, Names John P. McKearn, Ph.D., Venture Partner
7. Intellect Neurosciences, Inc. Receives Notice of Allowance and Completes Grant Requirements for Pivotal European Patent Related to Passive Immunization of Alzheimers Disease
8. Alimera Sciences, pSivida Limited Amend Medidur(TM) FA Collaboration Agreement
9. Matthew B. Potter Joins Pressure BioSciences, Inc. as Vice President of Sales
10. Pressure BioSciences, Inc. to Discuss 2007 Financial Results and Provide Business Update
11. DARA BioSciences, Inc. Announces Appointment of New Director to Board
Post Your Comments:
(Date:12/1/2015)... 2015  Symic, a clinical-stage biotherapeutics company developing multiple ... today announced that it has secured $25 million in ... including its lead candidates SB-030 and SB-061. The financing ... by all existing major investors, as well as several ... raised by Symic to over $43 million since being ...
(Date:12/1/2015)... ) has ... Virology and Bacteriology Testing Market: Sales and ... Shares by Test, Innovative Technologies, Competitive Strategies, ... --> ) has announced the ... Bacteriology Testing Market: Sales and Volume Segment ...
(Date:11/30/2015)... -- An interventional radiology technique shows promise for helping morbidly obese ... study being presented today at the annual meeting of the ... --> --> Gastric ... as a way to stop bleeding in emergency situations, but ... treating obesity is new. Mubin Syed , M.D., ...
(Date:11/30/2015)... Nov. 30, 2015 /PRNewswire/ - Zenith Epigenetics Corp. ("Zenith" or ... Norman C.W. Wong to its Board of Directors to ... Zenith with a wealth of experience as co-founder of Resverlogix, ... --> --> Dr. Wong ... board of directors. Zenith,s long standing expertise in epigenetics and ...
Breaking Biology Technology:
(Date:11/18/2015)... , Nov. 18, 2015  As new scientific ... children, doctors and other healthcare providers face challenges in ... families and patients. In addition, as more children continue ... a patient,s adulthood and old age. John ... The Children,s Hospital of Philadelphia (CHOP) . ...
(Date:11/17/2015)... , November 17, 2015 ... 19 novembre  2015.  --> Paris , ... --> DERMALOG, le leader de l,innovation biométrique, a ... fois passeports et empreintes sur la même surface de ... passeports et l,autre pour les empreintes digitales. Désormais, un ...
(Date:11/16/2015)... , Nov 16, 2015  Synaptics Inc. ... human interface solutions, today announced expansion of its ... ™ touch controller and display driver integration ... of smartphones. These new TDDI products add to ... (HD resolution), TD4302 (WQHD resolution), and TD4322 (FHD ...
Breaking Biology News(10 mins):